secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001104659-22-117755
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics reports Q3 net loss $6.6M; announces public offering of 5M shares at $1.20
--------------------------------------------------------------------------------

- Public offering of 5,000,000 shares at $1.20/share; gross proceeds $6.0M; net ~$5.4M; underwriter option for 750k additional shares.
- Q3 2022 net loss $6.6M ($0.29 diluted) vs $4.9M ($8.12) in Q3 2021; R&D expense $8.3M, G&A $4.4M.
- Cash $46.6M at Sept 30; $93.6M in awarded grants remain available; cash runway extended into first half 2024.
- Lead candidate CT1812 in three Phase 2 trials: SHINE expands to Europe, SEQUEL gets additional NIA grant, SHIMMER sites activating.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465922117755/0001104659-22-117755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465922117755/tm2230367d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer